# Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

Submission date	Recruitment status	[_] Prospectively registered		
15/08/2005	No longer recruiting	[] Protocol		
<b>Registration date</b> 09/09/2005	<b>Overall study status</b> Completed	Statistical analysis plan		
		[X] Results		
Last Edited 31/08/2022	Condition category Circulatory System	[_] Individual participant data		

### Plain English summary of protocol

Not provided at time of registration

# **Contact information**

**Type(s)** Scientific

**Contact name** Prof Rory Collins

### **Contact details**

Clinical Trial Service Unit Richard Doll Building Old Road Campus Oxford United Kingdom OX3 7LF +44 (0)1865 743743 Secretary@ctsu.ox.ac.uk

# Additional identifiers

EudraCT/CTIS number

#### **IRAS number**

ClinicalTrials.gov number NCT00124072

Secondary identifying numbers CTSU SEARCH1

# Study information

#### Scientific Title

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

#### Acronym

SEARCH

#### **Study objectives**

Do larger reductions in blood cholesterol produce larger, and worthwhile, reductions in cardiovascular risk, and does homocysteine-lowering with folic acid and vitamin B12 reduce cardiovascular risk?

Ethics approval required

Old ethics approval format

**Ethics approval(s)** Not provided at time of registration

**Study design** Randomised controlled trial

**Primary study design** Interventional

### Secondary study design

Randomised controlled trial

**Study setting(s)** Not specified

## Study type(s)

Treatment

#### Participant information sheet

Health condition(s) or problem(s) studied Coronary heart disease

#### Interventions

Simvastatin 80 mg versus 20 mg daily, and separately folic acid 2 mg plus 1 mg vitamin B12 daily or matching placebo tablets.

### Intervention Type

Supplement

**Phase** Not Specified

### Drug/device/biological/vaccine name(s)

Simvastatin, folic acid and vitamin B12

#### Primary outcome measure

Major vascular events (MVEs) during the scheduled treatment period

#### Secondary outcome measures

MVEs separately during the first year and in the later years of the study, MVEs in patients subdivided by pre-randomisation lipid levels, MVEs in the presence and absence of the other randomised treatments, major coronary events, total strokes

Overall study start date 30/07/1998

Completion date 31/12/2007

# Eligibility

#### **Key inclusion criteria** Men and women who have survivied a heart attack and in whom statin therapy is indicated.

Participant type(s) Patient

**Age group** Adult

**Sex** Both

**Target number of participants** 12,064

**Total final enrolment** 12064

#### Key exclusion criteria

Age under 18 years or over 80 at invitation, contraindications to either study drug, other predominant medical problem.

**Date of first enrolment** 30/07/1998

Date of final enrolment 31/12/2007

### Locations

**Countries of recruitment** England

United Kingdom

**Study participating centre Clinical Trial Service Unit** Oxford United Kingdom OX3 7LF

### Sponsor information

**Organisation** University of Oxford (UK)

Sponsor details University Offices Wellington Square Oxford England United Kingdom OX1 2JD +44 (0)1865 270000 search@ctsu.ox.ac.uk

**Sponsor type** University/education

Website http://www.ox.ac.uk

ROR https://ror.org/052gg0110

# Funder(s)

Funder type Industry

**Funder Name** A grant to Oxford University from Merck and Co.

# **Results and Publications**

### Publication and dissemination plan

Not provided at time of registration

#### Intention to publish date

### Individual participant data (IPD) sharing plan

Not provided at time of registration

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	21/08/2008		Yes	No
Results article	results	23/06/2010		Yes	No
Basic results			26/09/2019	No	No